3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Ovarian Neoplasms
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Ovarian Epithelial
1
Carcinoma
1
Brain Neoplasms
1
Interventions
Temozolomide
41
Radiotherapy
15
Magnetic Resonance Spectroscopy
12
Surgical Procedures, Operative
10
Bevacizumab
10
Irinotecan
9
Radiation
8
Nivolumab
7
Carmustine
7
Specimen Handling
6
Radiosurgery
6
Carboplatin
6
ribociclib
5
O(6)-benzylguanine
5
Imiquimod
5
IL13-PE38
5
Flucytosine
5
Filgrastim
5
Erlotinib Hydrochloride
5
Cyclophosphamide
5
Aminolevulinic Acid
5
vandetanib
4
sargramostim
4
Topotecan
4
Lomustine
4
Imatinib Mesylate
4
Etoposide
4
Craniotomy
4
vocimagene amiretrorepvec
3
temsirolimus
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Glioma
×
interferon gamma-1b
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled